Alliance Pharma plc

Equities

APH

GB0031030819

Pharmaceuticals

Market Closed - London S.E. 11:35:28 2024-04-25 am EDT 5-day change 1st Jan Change
34.9 GBX -0.29% Intraday chart for Alliance Pharma plc -5.03% -13.83%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
EARNINGS: Lok'n Store has "positive but muted" growth as Shurgard bids AN
Alliance Pharma plc Announces Delay in Publication of Preliminary Earnings Results for the Year Ended December 31, 2023 CI
Alliance Pharma appoints chair; FireAngel sales down AN
Alliance Pharma Chair to Step Down; Successor Named MT
Alliance Pharma plc Announces Board Changes CI
Jefferies raises Spirax-Sarco; cuts Victrex AN
Alliance Pharma reports annual boost in revenue; eyes flat 2024 profit AN
Alliance Pharma plc Announces Appointment of Non-Executive Directors CI
Barclays ups Rio Tinto; Liberum likes Indivior AN
Barclays cuts United Utilities and Severn Trent AN
Alliance Pharma first half profit plunges, stops dividend payout AN
Earnings Flash (APH.L) ALLIANCE PHARMA Posts H1 Revenue GBP81.4M MT
Earnings Flash (APH.L) ALLIANCE PHARMA Posts H1 EPS GBX0.94 MT
Alliance Pharma plc Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Alliance Pharma plc Provides Earnings Guidance for the Second Half of 2023 CI
High demand, low supplies for Novo's weight-loss drug launch in Germany RE
Exane raises Segro; Goldman likes Aston Martin AN
FTSE Closes Tuesday Up 0.6% Lifted by Banks, Oil Stocks; Ocado Soars DJ
UK Consumers Cut Spending Amid Rising Mortgage Rates DJ
Alliance Pharma interim see-through revenue climbs AN
Alliance Pharma votes approved despite sizeable opposition AN
FTSE 100 Closes Down 0.7% Dragged by Oil Stocks, US Debt-Ceiling Standoff DJ
BOE Rate Rise of More Than 25Bps Looks Unlikely DJ
Alliance Pharma annual profit "marginally below" forecasts AN
Alliance Pharma Four-Month Sales Rose on Year, But Sees Full-Year FX Hit DJ
Chart Alliance Pharma plc
More charts
Alliance Pharma plc is a United Kingdom-based consumer healthcare company. The principal activity of the Company is to act as a holding company. The principal activity of the Company is the acquisition, marketing and distribution of consumer healthcare and pharmaceutical products. The Company's segments are strategic business units that represent different parts of the overall product portfolio, these being Consumer Healthcare brands and Prescription Medicines. Its Consumer Healthcare brands include Kelo-Cote franchise, Amberen, Nizoral, MacuShield, Aloclair, Vamousse, and other consumer healthcare brands. Its Prescription Medicines include Hydromol, Flamma Franchise, Forceval and other prescription medicines. Its products include Aloclair Plus Gel, Changmin, Fazol Cream, Hydromol Ointment, Kelo-Stretch Cream, and others. It holds the marketing rights to around 80 Consumer Healthcare brands and Prescription Medicines, which are sold around the world in more than 100 countries.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
0.35 GBP
Average target price
0.6743 GBP
Spread / Average Target
+92.65%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. APH Stock
  4. News Alliance Pharma plc
  5. Alliance Pharma Completes Purchase Of Silicone-based Scar Treatment Brand From Ireland's Perrigo